Medium-Chain Triglycerides (MCTs) for the Symptomatic Treatment of Dementia-Related Diseases: A Systematic Review

Table 6

Intra- and intergroup effects of the MMSE.

Study	IG (pre)	IG (post)	IG difference	p (pre-post)	CG difference	IG-CG difference	p IG-CG
Chan et al. [51]	—	—	—	>0.05	—	—	>0.05
Farah [46] case report	23	28	+5.00	^a	—	—	—
Fortier et al. [57]	27.7 ± 2.2	—	—	>0.1	—	—	—
Henderson et al. [54]	19.48 ± 4.37
ITT	—	—	−0.206	—	−0.299	+0.09	0.8397
APOE^−	—	—	−0.276	—	+0.385	+0.66	0.3710
APOE^+	—	—	−0.474	—	−0.710	−0.24	0.7209
PP	—	—	−0.261	—	−0.178	+0.08	0.8925
APOE^−	—	—	−0.056	—	+0.684	+0.74	0.4502
APOE^+	—	—	−0.350	—	−0.913	+0.56	0.5362
DC	—	—	−0.136	—	−0.271	+0.13	0.8275
APOE^−	—	—	−0.125	—	+0.789	+0.9	0.3656
APOE^+	—	—	−0.136	—	−1.083	+0.95	0.2820
Henderson et al. [55]	20.8 ± 3.58
APOE^−	21.2 ± 3.49	∼20.6	−0.600	—	+0.100	+0.70	0.041
APOE^+	19.8 ± 3.62	∼18.8	−1.000	—	−0.800	−0.2	0.695
Juby et al. [43]^b
Group 1	23.8 ± 4.7	23.4 ± 5.5	−0.4	0.05	—	—	—
Group 2	22.8 ± 6.4	20.1 ± 7.7	−2.7		—	—	—
Maynard and Gelblum [62] cohort study	20.6 ± 3.0	20.1 ± 5.6	−0.480	0.5233	—	—	—
Maynard and Gelblum [40] case report	20.3	19	−0.640^c	—	−1.34^c	+0.7	0.3735^c
Newport et al. [41] case report	12	20	+8.00	—	—	—	—
Ohnuma et al. [42]					—	—	—
APOE^−	19.1 ± 6.0	∼19.17	∼+0.07	>0.05	—	—	—
APOE^+	17.8 ± 4.9	∼17.84	∼+0.04	>0.05	—	—	—

Calculated from the data. Estimated from figure. ^aBayesian values; before: significant deviation from norm; after: not significant. ^bResults after extension phase 3; crossover study design with additional extension phase. ^cMean annual rates of decline. IG = intervention group; CG = control group; ITT = intention to treat; PP = per protocol; DC = dosage compliant; APOE−/+ = APOE positive/negative.